Study of T320 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called T320 for people with advanced solid tumors that have not improved with standard treatments. The drug targets a protein on tumor cells to deliver chemotherapy directly to the cancer, possibly slowing growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has not responded to standard treatments, or there is no standard treatment available.
- You are 18 years or older.
- You can do light activities or are up and about more than half the day (ECOG 0-2).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, kidney, and heart function are adequate for the trial.
- You are willing to provide a tumor sample (old or new biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called ATB-320 in people whose cancer has spread or not responded to standard treatments. The goal is to first check if it is safe and tolerable, and to understand how it might help.
This trial tests an experimental drug, BNT3214, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if BNT3214 is safe and helps shrink tumors.
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
This trial tests a new oral drug, T-1301, for people with advanced solid tumors (including lymphoma) that have stopped responding to standard treatments. The study aims to find a safe dose and see how the body responds.
This trial tests a new drug called BNT3212, either alone or combined with BNT327, in people with advanced solid tumors that have not gotten better with standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.